
A Single Antiviral to Treat Multiple Opportunistic InfectionsAward last edited on: 2/1/2024
Sponsored Program
SBIRAwarding Agency
NIH : NIAIDTotal Award Amount
$5,126,080Award Phase
2Solicitation Topic Code
855Principal Investigator
Stacy W RemiszewskiCompany Information
Evrys Bio LLC (AKA: Forge Life Sciences LLC)
3805 Old Easton Road
Doylestown, PA 18902
Doylestown, PA 18902
(267) 893-6755 |
business@evrysbio.com |
www.forgelifescience.com |
Location: Single
Congr. District: 01
County: Bucks
Congr. District: 01
County: Bucks
Phase I
Contract Number: 1R43AI114079-01Start Date: 6/15/2014 Completed: 11/30/2014
Phase I year
2014Phase I Amount
$224,999Thesaurus Terms:
Address;Adenoviruses;Admission Activity;Adult;Adverse Effects;Agonist;Allogenic;Antiviral Agents;Asthma;Base;Binding (Molecular Function);Biochemical;Biological Sciences;Bk Virus;Boxing;Caloric Restriction;Central Nervous System Demyelinating Disorder;Chemicals;Cidofovir;Clinical;Commercialization;Communities;Cost;Cystitis;Cytomegalovirus;Cytopenia;Cytotoxic;Data;Deacetylase;Development;Diagnosis;Dialysis Procedure;Disease;Disease Management;Dissociation;Drug Resistance;Efalizumab;Effective Therapy;Effectiveness;Encephalitis;Enzyme Activation;Ganciclovir;Genetic;Goals;Graft Rejection;Growth;Healthcare;Hematopoietic Stem Cell Transplantation;Hepatitis B Virus;Hepatitis C Virus;Hepatitis Viruses;Herpesviridae;Herpesvirus 1, Human;High Risk;Hiv;Hiv Infections;Hospitalization;Human;Immune;Immune Response;Immune System;Immunocompromised Host;Immunoregulation;Immunosuppressed;Immunosuppressive Agents;Improved;In Vitro;In Vitro Assay;In Vitro Testing;In Vivo;Indexing;Infection;Influenza;Inhibitory Concentration 50;Intellectual Property;Jc Virus;Kidney;Kidney Diseases;Kidney Transplantation;Latent Virus;Lead;Length Of Stay;Licensing;Life;Longevity;Maintenance;Marketing;Maximum Tolerated Dose;Measures;Mediating;Medical;Meetings;Mission;Morbidity - Disease Rate;Mortality Vital Statistics;Mouse Model;Multiple Sclerosis;Natalizumab;Natural Immunosuppression;Nephrotoxic;Nephrotoxicity;Novel;Nuclear Magnetic Resonance;Opportunistic Infections;Organ;Organ Transplantation;Pathogen;Patients;Pharmaceutical Preparations;Phase;Plasma;Polyomavirus;Polyomavirus Infections;Progressive Multifocal Leukoencephalopathy;Property;Provider;Public Health Relevance;Quality Of Life;Red Wine;Respiratory Virus;Response;Resveratrol;Risk;Rituximab;Role;Scaffold;Seeds;Serologic Tests;Sirtuins;Small Business Innovation Research Grant;Small Molecule;Staging;Structure;Sum;Testing;Therapeutic;Therapeutic Immunosuppression;Therapeutic Index;Time;Transplant Recipients;Transplantation;Universities;Validation;Vigilance;Viral;Virus;Virus Diseases;Work;
Phase II
Contract Number: 2R44AI114079-02Start Date: 6/15/2014 Completed: 7/31/2022
Phase II year
2019(last award dollars: 2023)
Phase II Amount
$4,901,081Public Health Relevance Statement:
An overwhelming number of Americans require immune suppression of variable duration at some point in their lives due to various diseases from asthma to HIV to rheumatologic diseases to organ transplant - during the time at which their immune system is being suppressed these individuals are at great risk for developing an opportunistic viral infection. Standard of care therapeutic interventions for these patients are restricted by highly focused targeting of only select pathogens, the emergence of drug resistant strains, drug:drug interactions and adverse side effects. Successful completion of this application will result in the development of broad based antiviral compounds that 1) provide protection against highly diverse viruses, 2) limit the acquisition of drug resistance and 3) limit the liabilities associated with adverse side effects observed with current antivirals.
NIH Spending Category:
Antimicrobial Resistance; Digestive Diseases; Hepatitis; Hepatitis - B; Infectious Diseases; Liver Disease; Organ Transplantation; Transplantation
Project Terms:
Absorbable Gelatin Sponge; acquired drug resistance; Address; Adenoviruses; Affect; American; Animal Model; Antibiotics; Antipsychotic Agents; Antiviral Agents; Asthma; base; Biological Availability; Biological Sciences; candidate validation; Cavia; Cell physiology; Cells; Chemicals; Chemistry; clinical development; commercialization; Communities; Cytomegalovirus; Data; Detection; Development; Disease; Dose; Drug Exposure; Drug Interactions; Drug resistance; Drug Targeting; Effectiveness; Enzymes; expectation; Exposure to; Family; Fibroblasts; Ganciclovir; Goals; good laboratory practice; Graft Rejection; Growth; Hematopoietic Stem Cell Transplantation; Hepatitis B; Hepatitis B Virus; Hepatitis C virus; Hepatitis Viruses; Herpesviridae; Herpesvirus 1; high risk; HIV; Human; Immune system; Immunity; immunosuppressed; Immunosuppression; Implant; improved; In Vitro; in vivo; Individual; Infection; Influenza A virus; Influenza B Virus; inhibitor/antagonist; Intravenous; Investigational Drugs; Latent Virus; Lead; lead optimization; Life; Macaca mulatta; Measures; minimal risk; Mission; Modeling; Morbidity - disease rate; mortality; mouse model; Mus; nephrotoxicity; next generation; novel; Opportunistic Infections; Oral; Organ; Organ Transplantation; pathogen; Patients; penis foreskin; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Polyomavirus; post-transplant; pre-clinical; preclinical development; Primary Infection; Problem Solving; Production; programs; Prophylactic treatment; Proteins; Regimen; Reproducibility; Resistance; Resistance development; resistance mutation; resistant strain; respiratory virus; Risk; Route; SCID Mice; Series; side effect; Sirtuins; Small Business Innovation Research Grant; small molecule; standard of care; Structure of parenchyma of lung; Structure-Activity Relationship; synergism; Technology; Therapeutic; Therapeutic immunosuppression; Therapeutic Index; Therapeutic Intervention; Time; Toxicity Tests; Transplant Recipients; Transplantation; Triage; Universities; Valganciclovir; Validation; Vasoconstrictor Agents; Viral; Viral Drug Resistance; Viral Proteins; viral resistance; Virus; Virus Diseases; Virus Latency; Virus Replication